Vaxcyte Q1 2023 Earnings Report

Vaxcyte EPS Results

• Actual EPS: -$0.70
• Consensus EPS: -$0.80
• Beat/Miss: Beat by +$0.10
• One Year Ago EPS: N/A

Vaxcyte Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vaxcyte Announcement Details

• Quarter: Q1 2023
• Date: 5/8/2023
• Time: N/A
• Conference Call Date: Monday, May 8, 2023
• Conference Call Time: 4:00PM ET

Vaxcyte (NASDAQ:PCVX) is a clinical-stage biotechnology company headquartered in Redwood City, California, focused on the development of next-generation vaccines to prevent serious bacterial infections. The company’s research and development efforts center on creating multivalent conjugate vaccines that address high-unmet-need diseases caused by pathogens such as Streptococcus pneumoniae, group A Streptococcus and group B Streptococcus. By advancing candidates through preclinical studies and clinical trials, Vaxcyte aims to deliver improved protective immunization options over existing therapies.

Vaxcyte leverages a proprietary technology platform designed to enhance the immunogenicity and breadth of its vaccine candidates. This platform enables the efficient conjugation of bacterial polysaccharide antigens to carrier proteins, supporting the development of multivalent formulations with the potential to cover a wider array of serotypes. Among its pipeline assets are a 24-serotype pneumococcal conjugate vaccine and programs targeting streptococcal infections that continue to progress through Phase 1 and Phase 2 clinical evaluations.

The company was founded in 2016 as a spin-out from Sutro Biopharma by scientists experienced in vaccine antigen design and manufacturing. Since inception, Vaxcyte has built a team of research, clinical, and regulatory experts and has established state-of-the-art laboratories and manufacturing collaborations to support its programs. While headquartered in Northern California, the company’s clinical trials and strategic partnerships span the United States and select international regions with high burdens of bacterial disease.

Vaxcyte’s management team comprises industry veterans in vaccinology, biologics development and global regulatory affairs. Under the leadership of its board and executive officers, the company is working to advance its portfolio toward pivotal studies and regulatory submissions, with the overarching goal of delivering new preventive solutions that can reduce morbidity and mortality associated with bacterial infections worldwide.